Sanofi Says Beyfortus Will Be Broadly Available For Babies Born In Ontario, Quebec, Nunavut, Northwest Territories, And The Yukon This Fall
Sanofi Says Beyfortus Will Be Broadly Available For Babies Born In Ontario, Quebec, Nunavut, Northwest Territories, And The Yukon This Fall
賽諾菲表示，貝福特斯將於今年秋季在安大略省、魁北克省、努納武特領地、西北地區和育空地區爲新生兒廣泛提供。
Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season.
Beyfortus是加拿大首款獲批用於預防新生兒和嬰兒RSV下呼吸道疾病的長效抗體，在他們第一個RSV季節。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間